• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Pharma Pulse 10/18/24: Driving Diversity with the Integrated Research Model, More Treatment Options for Schizophrenia & more

News
Article

The latest news for pharma industry insiders.

Driving Diversity with the Integrated Research Model

Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.

More Treatment Options for Schizophrenia, More Decisions About Which One to Choose | AMCP Nexus 2024

Meanwhile, newly approved Cobenfy and the long-acting injectable antipsychotics may help with the long-standing problem of nonadherence to schizophrenia treatment.

Doctors, A.I. and Empathy for Patients

Dr. Reisman notes that ChatGPT’s answers to patient questions have been rated as more empathetic than those written by actual doctors. This should not be a call for doctors to surrender our human role to A.I. To the contrary, we need to continue to improve our communication skills.

Wisp Launches Comprehensive Weight Care Vertical to Support Women Struggling with Hormonal Imbalances

Wisp is now serving more than 1.2 million patients, today announced a significant expansion of its services with the introduction of its weight care vertical. Wisp will provide women with personalized, online healthcare consultations, offering four products, including GLP-1s, to help women struggling with hormonal imbalances due to conditions like perimenopause and menopause, Polycystic Ovary Syndrome (PCOS), and endometriosis. With this launch, the company debuts its first-ever exclusive over-the-counter weight care capsules, designed to promote women's metabolic health.

Rust Felix on LinkedIn

One of my favorite questions to ask during conversations with research sites is: “What are your thoughts on the current state of e-requisitions?”

The answer often involves one (or sometimes two) four-letter words.

The reason? Nearly all e-req solutions are designed for the lab’s needs, not the site’s processes. They fail to improve operational efficiency, making the work more cumbersome rather than easier.

This is why so many sites still prefer paper requisitions—despite their limitations—over e-reqs to document sample metadata. There’s a clear need for more site-centric solutions that streamline workflows and enhance operational efficiency.

At Slope, we’re committed to providing just that—tools that work for sites and improve their day-to-day processes.

Read more about my thoughts on this critical topic in my recent Q&A with Pharmaceutical Executive.

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs